September 14, 2021

Launched !! "VIRASPEC" Covid-19 test kit saliva type, convenient, rapid, easy to use, and high accuracy imported from Sweden certified European standards. It has been approved by the Thai FDA for both professional use and home use. Ready to be distributed throughout the country.

Bangkok – July 6, 2021: JBN Global Group Co., Ltd. has launched  JP World Medical Co., Ltd. (Thailand) to support the business of healthcare and medical equipment. Recently,   JP World Medical Co., Ltd. (Thailand) has launched the first product, Covid-19 test kit, a type of saliva detection named “VIRASPEC” SARS-CoV-2 Antigen Rapid Test Cassette (Saliva) certified to European standards.

JBN Global Group Co., Ltd. has received approval for registration of Rapid Antigen Test (Covid 19 test kit) for saliva detection from the Thai FDA on August 6, 2021, and has received approval for home use registration on September 10, 2021.

JP World Medical Co., Ltd. (Thailand) is the legal distributor of Viraspec SARS-CoV-2 Antigen Rapid Test Cassette (Saliva) of Thyrolytics AB, Sweden, with JBN Global. Group Co., Ltd. as the importer, JP Company has been entrusted as the main distributor in Thailand and also the sole distributor in 15 Asian countries including Vietnam, Myanmar, Philippines, Indonesia, Singapore, Brunei, Laos, Malaysia, Cambodia, Australia, India, Bangladesh, Japan, Pakistan, and Sri Lanka.

JP company’s mission is to join the fight against the Covid-19 pandemic so that people can access COVID-19 testing quickly to help reduce the number of infected people in the country. This test will help people go through the process of quarantining themselves from their families and those close to them in a timely manner before receiving further treatment according to medical advice.


Mr. Jacky Ong, President of JBN Global Group Co., Ltd. said: “At present, JBN has launched JP World Medical Co., Ltd. to support the importation of healthcare and medical equipment. As we are facing the Covid-19 pandemic, JP company has accelerated the distribution of the Rapid Antigen Test kit, the saliva detection  "VIRASPEC" imported from Sweden to the hands of Thai people.


There are many advantages such as it can be used easily, rapidly, without the difficulty of collecting samples from the nasal cavity or blood drawing. It is suitable for all ages, especially in children and for mass screening of people. We can quickly screen large numbers of people to reduce the outbreak of infection in a timely manner.”

Credit: Bangkok Post Group




September , 14 2021

As the only test based on saliva detection, Aegirbio's COVID-19 test has obtained marketing authorization from the Thai equivalent of the US FDA for introduction on the Thai market. The approval is for professional use, but we expect the test to be approved for home use as well in the near future.

The authorization opens up a market where Thailand and its neighbouring countries represent a catchment of more than 600 million inhabitants. The Company is already in contact with and making sales to a number of these countries and their respective authorities. Aegirbio is well prepared, and has, as previously announced, scaled up production to supply up to 9 million tests on a monthly basis. The Company is currently exploring ways to increase the rate of production even further. The spread of infection is high in the region, and the Government of Thailand has decided that Viraspec shall be an active part of the contact tracing effort. Our projection is that the need will remain at the same high level at least throughout 2022.

“That we succeeded in receiving authorization in Asia in such a short time is a big deal; the Thai FDA imposes just as strict requirements as the rest of the world, and this is evidence that our tests are up to the highest standards. It feels great to be able to contribute to the fight against the pandemic. The forecast for the Asian countries extends over a long time scope, and our products will be needed to suppress the spread. Our partner NowMed Sweden, in tandem with JP World Medical with responsibility for the Far East, have done a remarkable job thus far, and we have entrusted them 15 additional countries beyond Thailand. We are now looking forward to a similar development in those countries,” says Martin Linde, CEO of Aegirbio.

“We are proud to bring the first saliva-based test for COVID-19 from Europe to the Thai market. The rapid approval by the FDA is proof in itself. I am very pleased and proud of the opportunities that the authorization provides and look forward to introducing Viraspec in all our countries of operation,” says Jacky Ong, CEO of JP World Medical.

This information is information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (Regulation (EU) No 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 12:51 CET on 2021-08-06.

Aegirbio is a Swedish diagnostics company established to offer tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.

The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment, while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs, suboptimal clinical outcomes, and a higher proportion of patients suffering severe side effects.

The Company has completed acquisitions that ensure long-term access to key technologies and open up new application areas. Through these acquisitions, Aegirbio, rooted in laboratory testing, have in a short period of time added technologies and skills to the Company to make headway towards becoming the multidiagnostic company it has set out to be.

Aegirbio is now building its operations around technologies for

  • Rapid testing for indicative and quick results

  • Point of Need, quantitative home tests for chronic diseases

  • Point of Care, quantitative point-of-care tests for routine controls in clinics and health centres

  • Laboratory tests for monitoring patients treated with biological drugs.

The acquisitions provide the Company the means to develop new diagnostics to enable people to monitor their own health issues. In addition to bringing innovative diagnostic technology to market, the Company’s ambition in that regard is to make diagnostics more accurate, easier to use and with precise and easily transferable results.



Medical Team

April 14, 2021

Aegirbio is now ready to launch Viraspec Covid-19. The test is a saliva-based rapid test that is easy, quick and convenient to administer, without the discomfort of nasal swab testing. The consumer first collects saliva into a container containing a reagent, then pours the liquid onto the reagent stick. After a waiting period of five minutes, the result can be read from the stick, with a clear line indicating whether infection was detected.

Thanks to the various measures implemented to limit the spread and the increasing rate of vaccination in the population, the number of infected individuals is decreasing. Nevertheless, there will still be unlimited applications for a simple and precise test. For a long time to come, workplaces, schools, events and, not least, travel agencies will want to verify COVID-19 infection status before allowing admission to concerts and other gathering places. It will also facilitate the containment of outbreaks at workplaces or in schools significantly.


The product will be CE marked for professional use, and Aegirbio has initiated the process to make the test available to everyone. This is the starting point of a broad roll-out and enables us to launch the product across a number of continents at the same time.

“That we as a company have been able to develop a competitive product, obtain CE marking and launch it widely is a tremendous sign of strength. The current market is practically insatiable, and our ambition is to identify distributors that can help us put the product on several different markets. The decline of COVID-19 is a very positive development, but it will not impact the great demand for simple rapid tests, which in our assessment will remain for a long time to come. In addition, we have a preparedness for other variants of virus and will be able act fast if such a need arises. Finally, I would like to once again highlight the development team at Aegirbio, who have worked around the clock to make this happen,” says Martin Linde, CEO.